William Michael Dracup

Immunodiagnostic Systems Holdings Plc engages in the development, manufacture, and marketing of in-vitro diagnostic tests (IVD) to the clinical laboratory market. The company was founded in 1977 and is headquartered in Boldon, the United Kingdom.

Nonlinear Dynamics Ltd. develops data analysis software. Its products, Progenesis QI for small-molecule applications and Progenesis QI for proteomics applications, deliver highly-accurate quantitative data analysis with simplicity, scalability, statistical processing and improved visualizations. The company was founded in 1989 and is headquartered in Newcastle-upon-Tyne, the United Kingdom.

Joyce-Loebl Group Ltd. is a British company led by management.

Biosignatures Ltd. engages in medical informatics company that develops clinical biomarkers to help improve the diagnosis and treatment of disease. The company’s products are blood based diagnostic tests processed using a combination of proteomic separation and its analysis software technology. Its products include BiopSave that is used to tackle the clinical issue of the unnecessary biopsies used during the diagnosis process for prostate cancer; TigerPro, which identifies whether the patient has the aggressive form of prostate cancer or the indolent form; BladderSafe that replaces the current bladder cancer diagnostic processes; and RenalCheck for renal cancer. The company was founded by Will Dracup in May 21, 2007 and is headquartered in Newcastle Upon Tyne, the United Kingdom.

TotalLab Ltd. is a British company that provides medical image analysis software and 21 CFR Part 11 compliance solutions for the life science sector. The company was founded in 2007 and is based in Gosfort, UK. The company's Phoretix 1D Advanced Western Blot Image Analysis software allows for easy analysis of 1D gels, Western blots, and other immunoblots. TotalLab's software solutions are designed to meet 21 CFR Part 11 and GXP compliance requirements, enabling researchers and scientists to achieve accurate results while maintaining regulatory compliance.